PE20150623A1 - Moduladores de la ruta del complemento y usos de los mismos - Google Patents
Moduladores de la ruta del complemento y usos de los mismosInfo
- Publication number
- PE20150623A1 PE20150623A1 PE2014001943A PE2014001943A PE20150623A1 PE 20150623 A1 PE20150623 A1 PE 20150623A1 PE 2014001943 A PE2014001943 A PE 2014001943A PE 2014001943 A PE2014001943 A PE 2014001943A PE 20150623 A1 PE20150623 A1 PE 20150623A1
- Authority
- PE
- Peru
- Prior art keywords
- halogen
- alkyl
- modulators
- alkoxy
- amino
- Prior art date
Links
- 230000000295 complement effect Effects 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 102000003712 Complement factor B Human genes 0.000 abstract 1
- 108090000056 Complement factor B Proteins 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 1
- 230000024203 complement activation Effects 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261642798P | 2012-05-04 | 2012-05-04 | |
| US201361782820P | 2013-03-14 | 2013-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20150623A1 true PE20150623A1 (es) | 2015-05-17 |
Family
ID=48626502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2014001943A PE20150623A1 (es) | 2012-05-04 | 2013-05-03 | Moduladores de la ruta del complemento y usos de los mismos |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP2855456B1 (https=) |
| JP (1) | JP6180514B2 (https=) |
| KR (1) | KR20150003903A (https=) |
| CN (1) | CN104603127B (https=) |
| AP (1) | AP2014008040A0 (https=) |
| AR (1) | AR090945A1 (https=) |
| AU (1) | AU2013255470B2 (https=) |
| BR (1) | BR112014027359A2 (https=) |
| CA (1) | CA2872000A1 (https=) |
| CL (1) | CL2014002919A1 (https=) |
| CR (1) | CR20140508A (https=) |
| EA (1) | EA027113B1 (https=) |
| ES (1) | ES2630079T3 (https=) |
| HK (1) | HK1206017A1 (https=) |
| IL (1) | IL235362A0 (https=) |
| MX (1) | MX2014013428A (https=) |
| PE (1) | PE20150623A1 (https=) |
| PH (1) | PH12014502462A1 (https=) |
| PL (1) | PL2855456T3 (https=) |
| PT (1) | PT2855456T (https=) |
| SG (1) | SG11201406973PA (https=) |
| TN (1) | TN2014000449A1 (https=) |
| TW (1) | TW201348199A (https=) |
| UY (1) | UY34781A (https=) |
| WO (1) | WO2013164802A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2970269B1 (en) * | 2013-03-14 | 2017-04-19 | Novartis AG | 2-(1h-indol-4-ylmethyl)-3h-imidazo[4,5-b]pyridine-6-carbonitrile derivatives as complement factor b inhibitors useful for the treatment of ophthalmic diseases |
| JO3425B1 (ar) | 2013-07-15 | 2019-10-20 | Novartis Ag | مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b |
| EP3089963A1 (en) * | 2013-10-30 | 2016-11-09 | Novartis AG | 2-benzyl-benzimidazole complement factor b inhibitors and uses thereof |
| CN103755622A (zh) * | 2013-12-25 | 2014-04-30 | 华东理工大学 | 合成4,5,6,7-四氘代吲哚-3-乙酸的方法 |
| WO2017035408A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Compounds for treatment of immune and inflammatory disorders |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| TWI854164B (zh) | 2016-02-01 | 2024-09-01 | 美商百歐克斯製藥公司 | 苯并吡唑化合物及其類似物 |
| RU2018145364A (ru) * | 2016-06-27 | 2020-07-28 | Ачиллион Фармасьютикалс, Инк. | Хиназолиновые и индольные соединения для лечения медицинских нарушений |
| CN110603252A (zh) | 2017-03-01 | 2019-12-20 | 艾其林医药公司 | 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物 |
| TWI873092B (zh) * | 2018-04-06 | 2025-02-21 | 美商百歐克斯製藥公司 | 取代的苯并呋喃、苯并吡咯、苯并噻吩及結構相關的補體抑制劑 |
| WO2020041301A1 (en) | 2018-08-20 | 2020-02-27 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement factor d medical disorders |
| WO2020051532A2 (en) | 2018-09-06 | 2020-03-12 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for the treatment of medical disorders |
| US11814363B2 (en) | 2018-09-06 | 2023-11-14 | Achillion Pharmaceuticals, Inc. | Morphic forms of danicopan |
| BR112021005506A2 (pt) | 2018-09-25 | 2021-06-15 | Achillion Pharmaceuticals, Inc. | formas mórficas de inibidores de fator complementar d |
| WO2021168320A1 (en) | 2020-02-20 | 2021-08-26 | Achillion Pharmaceuticals, Inc. | Heteroaryl compounds for treatment of complement factor d mediated disorders |
| CA3179686A1 (en) * | 2020-04-07 | 2021-10-14 | UCB Biopharma SRL | Difluorocyclohexyl derivatives as il-17 modulators |
| CN114057758A (zh) | 2020-08-07 | 2022-02-18 | 上海美悦生物科技发展有限公司 | 补体因子b抑制剂及其药物组合物、制备方法和用途 |
| EP4194449A4 (en) | 2020-08-07 | 2024-03-20 | Shanghai Meiyue Biotech Development Co., Ltd. | Heterocyclic compound, preparation method therefor and use thereof |
| WO2022066774A1 (en) | 2020-09-23 | 2022-03-31 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement mediated disorders |
| US20240287034A1 (en) * | 2021-06-03 | 2024-08-29 | Chinook Therapeutics, Inc. | Substituted indole compounds and methods of use thereof |
| CA3242815A1 (en) | 2022-01-26 | 2023-08-03 | Shanghai Meiyue Biotech Development Co., Ltd. | Salt type and crystal form of complement factor b inhibitor, and preparation method therefor and application thereof |
| CN119137099A (zh) * | 2022-04-01 | 2024-12-13 | 诺华股份有限公司 | 补体因子b抑制剂及其用途 |
| EP4617266A1 (en) | 2022-11-11 | 2025-09-17 | Shanghai Yisheng Biopharmaceutical company Limited | Piperidine-substituted benzoic acid compound, and pharmaceutical composition and use thereof |
| JP2026502231A (ja) * | 2022-12-31 | 2026-01-21 | チューハイ ユナイテッド ラボラトリーズ シーオー．，エルティーディー． | 補体因子ｂ阻害剤、その医薬組成物および使用 |
| IL325759A (en) | 2023-07-04 | 2026-03-01 | Sitala Bio Ltd | History of 2-(1H-indol-4-yl)methyl)2H-indazole as factor B inhibitors |
| IL325760A (en) | 2023-07-04 | 2026-03-01 | Sitala Bio Ltd | History of 2-(1H-indol-4-yl)methyl)-isoindoline as factor B inhibitors |
| WO2025008516A2 (en) | 2023-07-06 | 2025-01-09 | Sitala Bio Ltd | Novel compounds |
| WO2025008517A1 (en) | 2023-07-06 | 2025-01-09 | Sitala Bio Ltd | Indole derivatives with factor b inhibitory activity |
| CN119371402A (zh) | 2023-07-26 | 2025-01-28 | 上海美悦生物科技发展有限公司 | 螺环烯基类或氮杂烯基类化合物及其药物组合物、制备方法和用途 |
| WO2025172535A1 (en) | 2024-02-15 | 2025-08-21 | Sitala Bio Ltd | Indole and benzimidazole compounds as factor b inhibitors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| GB8420919D0 (en) * | 1984-08-17 | 1984-09-19 | Beecham Group Plc | Compounds |
| DE19545464A1 (de) * | 1995-12-06 | 1997-06-12 | Bayer Ag | Benzimidazol-isoindoleninfarbstoffe |
| CN100415723C (zh) * | 2000-01-17 | 2008-09-03 | 帝人株式会社 | 苯并咪唑衍生物 |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| GB0400781D0 (en) * | 2004-01-14 | 2004-02-18 | Novartis Ag | Organic compounds |
| US7488752B2 (en) * | 2004-10-08 | 2009-02-10 | Schering Corporation | Thrombin receptor antagonists |
| WO2007034277A1 (en) * | 2005-09-19 | 2007-03-29 | Pfizer Products Inc. | Aryl substituted imidazo [4,5-c] pyridine compounds as c3a receptor antagonists |
| EP2046741B1 (en) * | 2006-07-03 | 2012-10-31 | Proximagen Ltd. | Indoles as 5-ht6 modulators |
| JO3265B1 (ar) * | 2008-12-09 | 2018-09-16 | Novartis Ag | مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض |
| CA2965223C (en) * | 2008-12-22 | 2019-09-24 | Chemocentryx, Inc. | C5ar antagonists |
| AU2010216239B2 (en) * | 2009-02-18 | 2012-06-14 | Amgen Inc. | Indole/benzimidazole compounds as mTOR kinase inhibitors |
| EP2447263A1 (en) * | 2010-09-27 | 2012-05-02 | Bioprojet | Benzazole derivatives as histamine H4 receptor ligands |
| US8846656B2 (en) * | 2011-07-22 | 2014-09-30 | Novartis Ag | Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators |
-
2013
- 2013-05-03 EP EP13729096.1A patent/EP2855456B1/en active Active
- 2013-05-03 KR KR1020147033713A patent/KR20150003903A/ko not_active Withdrawn
- 2013-05-03 EA EA201492023A patent/EA027113B1/ru not_active IP Right Cessation
- 2013-05-03 MX MX2014013428A patent/MX2014013428A/es unknown
- 2013-05-03 PT PT137290961T patent/PT2855456T/pt unknown
- 2013-05-03 CN CN201380035327.6A patent/CN104603127B/zh not_active Expired - Fee Related
- 2013-05-03 AP AP2014008040A patent/AP2014008040A0/xx unknown
- 2013-05-03 BR BR112014027359A patent/BR112014027359A2/pt not_active IP Right Cessation
- 2013-05-03 SG SG11201406973PA patent/SG11201406973PA/en unknown
- 2013-05-03 ES ES13729096T patent/ES2630079T3/es active Active
- 2013-05-03 PE PE2014001943A patent/PE20150623A1/es not_active Application Discontinuation
- 2013-05-03 JP JP2015509561A patent/JP6180514B2/ja not_active Expired - Fee Related
- 2013-05-03 CA CA2872000A patent/CA2872000A1/en not_active Abandoned
- 2013-05-03 AU AU2013255470A patent/AU2013255470B2/en not_active Ceased
- 2013-05-03 TW TW102115970A patent/TW201348199A/zh unknown
- 2013-05-03 UY UY0001034781A patent/UY34781A/es not_active Application Discontinuation
- 2013-05-03 WO PCT/IB2013/053546 patent/WO2013164802A1/en not_active Ceased
- 2013-05-03 PL PL13729096T patent/PL2855456T3/pl unknown
- 2013-05-03 HK HK15106552.0A patent/HK1206017A1/xx unknown
- 2013-05-06 AR ARP130101533A patent/AR090945A1/es unknown
-
2014
- 2014-10-22 TN TN2014000449A patent/TN2014000449A1/fr unknown
- 2014-10-27 IL IL235362A patent/IL235362A0/en unknown
- 2014-10-28 CL CL2014002919A patent/CL2014002919A1/es unknown
- 2014-11-04 PH PH12014502462A patent/PH12014502462A1/en unknown
- 2014-11-04 CR CR20140508A patent/CR20140508A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013255470A1 (en) | 2014-11-13 |
| EP2855456B1 (en) | 2017-03-29 |
| IL235362A0 (en) | 2014-12-31 |
| CR20140508A (es) | 2015-03-13 |
| HK1206017A1 (en) | 2015-12-31 |
| AU2013255470B2 (en) | 2015-09-17 |
| CL2014002919A1 (es) | 2015-07-03 |
| WO2013164802A1 (en) | 2013-11-07 |
| PH12014502462A1 (en) | 2014-12-22 |
| AP2014008040A0 (en) | 2014-10-31 |
| TW201348199A (zh) | 2013-12-01 |
| PL2855456T3 (pl) | 2017-09-29 |
| BR112014027359A2 (pt) | 2017-07-18 |
| CN104603127A (zh) | 2015-05-06 |
| CA2872000A1 (en) | 2013-11-07 |
| JP6180514B2 (ja) | 2017-08-16 |
| EA201492023A1 (ru) | 2015-03-31 |
| PT2855456T (pt) | 2017-07-10 |
| KR20150003903A (ko) | 2015-01-09 |
| UY34781A (es) | 2013-12-31 |
| SG11201406973PA (en) | 2014-12-30 |
| AR090945A1 (es) | 2014-12-17 |
| CN104603127B (zh) | 2016-10-05 |
| TN2014000449A1 (en) | 2016-03-30 |
| JP2015515976A (ja) | 2015-06-04 |
| ES2630079T3 (es) | 2017-08-17 |
| MX2014013428A (es) | 2015-02-04 |
| EA027113B1 (ru) | 2017-06-30 |
| EP2855456A1 (en) | 2015-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20150623A1 (es) | Moduladores de la ruta del complemento y usos de los mismos | |
| PE20151064A1 (es) | Nuevos derivados tienopirimidina, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| DOP2016000208A (es) | Benzimidazol-2-aminas como inhibidores de midh1 | |
| CR20140089A (es) | Nuevos derivados bicíclicos de dihidroquinolina-2-ona | |
| EA201590053A1 (ru) | Модуляторы пути системы комплемента и их применение | |
| PE20150776A1 (es) | 6-aminoacido-heteroarildihidropirimidinas para el tratamiento y profilaxis de la infeccion del virus de la hepatitis b | |
| PE20142339A1 (es) | Derivados macrociclicos para el tratamiento de enfermedades | |
| ECSP15012804A (es) | Alcoxipirazoles como activadores de guanilato ciclasa soluble | |
| PE20150684A1 (es) | Compuestos triciclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr) | |
| CR20130333A (es) | Compuestos indol o análogos de los mismos útiles en el tratamiento de la degeneración macular relacionada con la edad (dmae) | |
| PE20121695A1 (es) | 5-alquinil-pirimidinas | |
| UY32916A (es) | Nuevas pirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones | |
| PE20151090A1 (es) | Lactamas fusionadas de arilo y heteroarilo | |
| PE20141678A1 (es) | Indazol-3-carboxamidas y su uso como inhibidores de la ruta de senalizacion de wnt/b-catenina | |
| UY32543A (es) | Análogos de isoxazol-3(2h)-ona como agentes terapéuticos | |
| PE20170666A1 (es) | 2-(morfolin-4-il)-1,7-naftiridinas | |
| ECSP14013217A (es) | 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk. | |
| UY32462A (es) | Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644 | |
| ECSP14013245A (es) | Nuevos derivados dihidroquinolina-2-ona | |
| DOP2014000156A (es) | Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| PE20180024A1 (es) | Triazolopirazinonas como inhibidores de pde1 | |
| ECSP14013215A (es) | Compuestos novedosos | |
| PE20150966A1 (es) | Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina | |
| PE20141352A1 (es) | Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento | |
| PE20142366A1 (es) | Compuestos triazolo como inhibidores de pde 10 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |